Last reviewed · How we verify
NCT05066139: EPODIG-G
Multidisciplinary Evaluation of Elderly Patients With Digestive Cancer (EPODIG-G)
NA trial testing EPODIG-G program (coordination of supportive care) in Digestive System Disease in 144 participants. Currently enrolling.
17 October 2030
Quick facts
| Lead sponsor | Centre Paul Strauss |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 144 |
| Start date | 17 September 2021 |
| Primary completion | 17 October 2030 |
| Estimated completion | 17 October 2030 |
| Sites | 1 location across France |
Drugs / interventions tested
- EPODIG-G program (coordination of supportive care)
Conditions studied
- Digestive System Disease — all drugs for Digestive System Disease →
- Neoplasms — all drugs for Neoplasms →
Sponsor
Centre Paul Strauss — full company profile →
Who can join
75 and older, any sex, with Digestive System Disease or Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a monocentric, comparative, open-label, randomized parallel group study enrolling elderly subjects hospitalized in Strasbourg Europe Cancerology Institute (ICANS), starting chemotherapy or targeted therapy for the treatment of digestive cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05066139
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Digestive System Disease
Currently open trials in the same condition.
- NCT06271538 — Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome · Phase 4 · recruiting
- NCT05612347 — Colonoscopy vs Stool Testing for Older Adults With Colon Polyps · NA · recruiting
- NCT05209568 — Immune Responses to Gluten · NA · recruiting
- NCT05489237 — First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors · Phase 1 · recruiting
- NCT04493632 — OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry. · recruiting
Other Centre Paul Strauss trials
Trials by the same sponsor.
- NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
- NCT07204535 — Post-TRaUmatic STress Disorder Induced by Gynecological Brachytherapy · not yet recruiting
- NCT07069790 — Effects of Chemotherapy Treatment on Metaboreflex, Mechanoreflex, and Baroreflex Function: PROTECT-08B Study · NA · recruiting
- NCT05653622 — Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operate · Phase 2 · recruiting
- NCT06330142 — Hippotherapy Teenager-pediatric Radiotherapy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05066139 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Paul Strauss
- Last refreshed: 5 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05066139.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing